• Publications
  • Influence
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk and the lifestyle intervention was more effective than meetformin. Expand
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity. Expand
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.
Age, personal or family history of fracture, Asian or Hispanic heritage, smoking, and cortisone use were associated with significantly increased likelihood of osteoporosis; higher body mass index, African American heritage, estrogen or diuretic use, exercise, and alcohol consumption significantly decreased the likelihood. Expand
Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis
Harry K. Genant (Chairman) , Cyrus Cooper (Rapporteur) , Gyula Poor (Rapporteur) , Ian Reid (Rapporteur) , George Ehrlich (Editor), J. Kanis (Editor), B. E. Christopher Nordin (Editor), Elizabet hExpand
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study
Obesity in middle age increases the risk of future dementia independently of comorbid conditions. Expand
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
A strategy to reduce overall fracture incidence will likely require lifestyle changes and a targeted effort to identify and develop treatment protocols for women with less severe low bone mass who are nonetheless at increased risk for future fractures. Expand
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis, and no new safety concerns related to ral oxifene therapy were identified during CORE. Expand
Osteoporosis and Fracture Risk in Women of Different Ethnic Groups
Osteoporosis and 1‐year fracture risk were studied in 197,848 postmenopausal American women from five ethnic groups. Weight explained differences in BMD, except among blacks, who had the highest BMD.Expand
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke. Expand
The prevalence of peripheral arterial disease in a defined population.
Assessment of large-vessel PAD prevalence by intermittent claudication dramatically underestimated the true large- Vessel P AD prevalence and assessment by peripheral pulse examination dramatically overestimated the true prevalence. Expand